Literature DB >> 19741190

How I treat postthrombotic syndrome.

Susan R Kahn1.   

Abstract

Postthrombotic syndrome (PTS) is a chronic complication of deep venous thrombosis (DVT) that reduces quality of life and has important socioeconomic consequences. More than one-third of patients with DVT will develop PTS, and 5% to 10% of patients will develop severe PTS, which may manifest as venous ulceration. The principal risk factors for PTS are persistent leg symptoms 1 month after the acute episode of DVT, extensive DVT, recurrent ipsilateral DVT, obesity, and older age. Daily use of elastic compression stockings (ECSs) for 2 years after proximal DVT appears to reduce the risk of PTS; however, there is uncertainty about optimal duration of use and compression strength of ECSs and the magnitude of their effect. The cornerstone of managing PTS is compression therapy, primarily using ECSs. Venoactive medications such as aescin and rutoside may provide short-term relief of PTS symptoms. The likelihood of developing PTS after DVT should be discussed with patients, and symptoms and signs of PTS should be monitored during clinical follow-up. Further studies to elucidate the pathophysiology of PTS, to identify clinical and biologic risk factors, and to test new preventive and therapeutic approaches to PTS are needed to ultimately improve the long-term prognosis of patients with DVT.

Entities:  

Mesh:

Year:  2009        PMID: 19741190     DOI: 10.1182/blood-2009-07-199174

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline.

Authors:  David Liu; Erica Peterson; James Dooner; Mark Baerlocher; Leslie Zypchen; Joel Gagnon; Michael Delorme; Chad Kim Sing; Jason Wong; Randolph Guzman; Gavin Greenfield; Otto Moodley; Paul Yenson
Journal:  CMAJ       Date:  2015-09-28       Impact factor: 8.262

Review 2.  Deep Vein Thrombosis Interventions in Cancer Patients.

Authors:  Resmi Ann Charalel; Suresh Vedantham
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

3.  Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial.

Authors:  Susan R Kahn; Ian Shrier; Stan Shapiro; Adrielle H Houweling; Andrew M Hirsch; Robert D Reid; Clive Kearon; Khalil Rabhi; Marc A Rodger; Michael J Kovacs; David R Anderson; Philip S Wells
Journal:  CMAJ       Date:  2010-11-22       Impact factor: 8.262

Review 4.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

5.  "Early thrombus removal" in iliac-femoral deep vein thrombosis for prevention of post-thrombotic syndrome.

Authors:  Benilde Cosmi; Gualtiero Palareti
Journal:  Ann Transl Med       Date:  2019-12

6.  The direct oral anticoagulants may also be effective against the risk of post-thrombotic syndrome.

Authors:  Gualtiero Palareti; Benilde Cosmi
Journal:  Intern Emerg Med       Date:  2019-12-23       Impact factor: 3.397

7.  Outcomes in children with deep vein thrombosis managed with percutaneous endovascular thrombolysis.

Authors:  Christopher E Dandoy; Kamlesh U Kukreja; Ralph A Gruppo; Manish N Patel; Cristina Tarango
Journal:  Pediatr Radiol       Date:  2014-11-07

8.  The post-thrombotic syndrome: a 2012 therapeutic update.

Authors:  Jean-Philippe Galanaud; Susan R Kahn
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-04

Review 9.  DVT Intervention in the Post-ATTRACT Era.

Authors:  Ronald S Winokur; Akhilesh K Sista
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-06

10.  A novel hollow and perforated flexible wire allows the safe and effective local application of thrombolytic therapy in a mouse model of deep vein thrombosis.

Authors:  Thilo Witsch; Maximilian Mauler; Nadine Herr; Daniela Stallmann; Christoph Bode; Christoph Hehrlein; Daniel Duerschmied
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.